Arbutus Biopharma Corporation
ABUS • NASDAQ
Arbutus Biopharma Corporation is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Lindsay Androski, with a market cap of $838.6M.
CEOLindsay Androski
Next Earnings
Upcoming earnings announcement for Arbutus Biopharma Corporation
Date
Wednesday, May 13, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.06
Revenue Estimate
$547.0K
Earnings History
Past 12 earnings reports for Arbutus Biopharma Corporation
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Q4 2025 | -$0.01Est: -$0.04 | +75.0% | $1.1MEst: $829.0K | +26.8% |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.04Est: -$0.04 | 0.0% | $529.0KEst: $1.3M | -59.6% | 10-Q |
| Aug 6, 2025 | Q2 2025 | $0.01Est: -$0.06 | +116.7% | $10.7MEst: $2.0M | +424.4% | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.13Est: -$0.15 | +13.3% | $1.8MEst: $2.3M | -23.0% | 10-Q |
| Mar 27, 2025 | Q4 2024 | -$0.07Est: -$0.12 | +41.7% | $1.6MEst: $2.2M | -28.8% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.10Est: -$0.09 | -11.1% | $1.3MEst: $1.9M | -28.0% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$0.11Est: -$0.10 | -10.0% | $1.7MEst: $1.8M | -1.4% | 10-Q |
| May 2, 2024 | Q1 2024 | -$0.10Est: -$0.11 | +9.1% | $1.5MEst: $2.2M | -28.7% | 10-Q |
| Feb 29, 2024 | Q4 2023 | -$0.12Est: -$0.12 | 0.0% | $2.1MEst: $4.8M | -55.2% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.12Est: -$0.11 | -9.1% | $4.7MEst: $4.8M | -1.9% | — |
| Aug 3, 2023 | Q2 2023 | -$0.10Est: -$0.12 | +16.7% | $4.7MEst: $5.0M | -7.4% | 10-Q |
| May 4, 2023 | Q1 2023 | -$0.10Est: -$0.14 | +28.6% | $6.7MEst: $6.0M | +10.9% | — |